METAPROTERENOL SULFATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Metaproterenol Sulfate, and when can generic versions of Metaproterenol Sulfate launch?
Metaproterenol Sulfate is a drug marketed by Apotex Inc, Astrazeneca, DEY, Mylan Speciality Lp, Nephron, Wockhardt, Cosette, G And W Labs Inc, Genus, Morton Grove, Am Therap, Heritage Pharma, Strides Pharma, Usl Pharma, and Watson Labs. and is included in twenty-nine NDAs.
The generic ingredient in METAPROTERENOL SULFATE is metaproterenol sulfate. There are six drug master file entries for this compound. Additional details are available on the metaproterenol sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Metaproterenol Sulfate
A generic version of METAPROTERENOL SULFATE was approved as metaproterenol sulfate by GENUS on July 22nd, 1992.
Summary for METAPROTERENOL SULFATE
US Patents: | 0 |
Applicants: | 15 |
NDAs: | 29 |
Raw Ingredient (Bulk) Api Vendors: | 58 |
Patent Applications: | 1,724 |
Formulation / Manufacturing: | see details |
DailyMed Link: | METAPROTERENOL SULFATE at DailyMed |